Male breast carcinoma: Epidemiology, risk factors and current therapeutic approaches

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 15-19

  Zygogianni, Anna G ^a   Kyrgias, George ^b   Gennatas, Costantinos ^a   Ilknur, Aytas ^c   Armonis, Vassilios ^d   Tolia, Maria ^e   Papaloukas, Christos ^f   Pistevou, Gompaki ^f   Kouvaris, John ^a   Kouloulias, Vassilios ^e  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c Ankara Numune Research and Educational Hospital   (Turkey)

^d Oncological Hospital of IKA   (Greece)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^f AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Epidemiology; Male breast cancer; Review; Treatment

Indexed keywords

BREAST TUMOR; HUMAN; MALE; REVIEW; RISK FACTOR;

BREAST NEOPLASMS, MALE; HUMANS; MALE; RISK FACTORS;

EID: 84864877059     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.015     Document Type: Short Survey

References (50)

1. Anderson F, Jatoi I, Tse J, Rosenberg S (2010). Male breast cancer: A population-based comparison with female breast cancer. J Clin Oncol, 28, 232-9.
2. ASCO Working Group on Genetic Testing for Cancer Susceptibility: American Society of Clinical Oncology Policy Statement Update: geneting testing for cancer Susceptibility. (2007) J Clin Oncol, 21, 2397-406.
3. Bergh J, Jönsson P, Glimelius B, Nygren P (2001). A systematic overview of chemotherapy effects in breast cancer, Acta Oncol, 40, 253-81.
4. Boughey J, Bedrosian I, Meric-Bernstam F, et al (2006). Comparative analysis of sentinel lymph node operation in male and female breast cancer patients, J Am Coll Surg, 203, 475-80.
5. Brinton A, Richesson A, Gierach L, et al (2008). Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst, 100, 1477-81.
6. Buzdar A, Ibrahim N, Francis D, et al (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 23, 3676-85.
7. Chianakwalam C, McCahy P, Griffiths N (2005). A case of male breast cancer in association with bicalutamide-induced gynaecomastia, Breast, 14, 163-4.
8. Cimmino V, Degnim A, Sabel M, et al (2004), Efficacy of sentinel lymph node biopsy in male breast cancer, J Surg Oncol, 86, 74-7.
9. Clarke M, Collins R, Darby S, et al (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials, Lancet, 366, 2087-106.
10. Coard K, McCartney T (2004). Bilateral synchronous carcinoma of the male breast in a patient receiving estrogen therapy for carcinoma of the prostate: cause or coincidence, South Med J, 97, 308-10.
11. Contractor B, Kaur K, Rodrigues S, Kulkarni M, Singhal H (2008). Male breast cancer: is the scenario changing, World J Surg Oncol, 6, 58.
12. Cutuli B (2007). Strategies in treating male breast cancer, Expert Opin Pharmacother, 8, 193-202.
13. Cutuli B, Lacroze M, Dilhuydy J, et al (1995). Male breast cancer: results of the treatments and prognostic factors in 397 cases, Eur J Cancer, 31A, 1960-4.
14. Cutuli B, Borel C, Dhermain F, et al (2001). Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases, Radiother Oncol, 59, 247-55.
15. Daly B (2009). The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling, J Genet Couns, 18, 42-8.
16. Dicker P (2003). The safety and tolerability of low dose irradiation for the management of gynaecomastia caused by antdrogen monotherapy, Lancet Oncol, 4, 30-6.
17. Donegan W, Redlich P, Lang P, Gall M (1998). Carcinoma of the breast in males: a multiinstitutional survey. Cancer, 83, 498-509.
18. Fisher B, Slack N, Katrych D, Wolmark N (1975), Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet, 140, 528-34.
19. Forloni F, Giovilli M, Pecis C, et al (2001). Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest, 24, 454-9.
20. Gancberg D, Di Leo A, Cardoso F, et al (2002), Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol, 13, 1036-43.
21. Gennari R, Curigliano G, Jereczek-Fossa B, et al (2004). Male breast cancer: a special therapeutic problem. Anything new, Int J Oncol, 24, 663-70.
22. Giordano S, Cohen D, Buzdar A, Perkins G, Hortobagyi G (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7.
23. Giordano S, Perkins G, Broglio K, et al (2005). Adjuvant systemic therapy for male breast carcinoma. Cancer, 104, 2359-64.
24. Handesman D (2001). Androgen action and pharmacologic uses. In Endocrinology, 2232-42, Eds Degroot A.
25. Hooning M, Botma A, Aleman B, et al (2007). Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst, 99, 365-75.
26. Lanitis S, Rise J, Vaughan A, et al (2008). Diagnosis and management of male breast cancer. World J Surg, 32, 2471-76.
27. Levy-Lahad E, Friedman E (2007). Cancer risks among BRCA1 and BRCA2 mutation carriers. BR J Cancer, 96, 11-5.
28. Macdonald G, Paltiel C, Olivotto I, Tyldesley S (2005). A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol, 16, 1442-8.
29. Mauras N, O'Brien K, Klein K, Hayes V (2000). Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab, 85, 2370-7.
30. Meijers-Heijboer H, Van den Ouweland A, Klijn J, et al (2002). CHEK2-Breast Cancer Consortium, Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet, 31, 55-9.
31. Mohamad B, Apffelstaedt P (2008). Counseling for male BRCA mutation carriers: a review. Breast, 17, 441-50.
32. Nahleh Z (2006), Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev, 32, 101-5.
33. Nordenskjold, B Rosell J, Rutqvist L, et al (2005). Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial, J Natl Cancer Inst 97, 1609-10.
34. O'Malley C, Prehn A, Shema S, Glaser S (2002). Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer, 94, 2836-43.
35. Ottini, Rizzolo, Zanna , et al (2009). BRCA1/BRCA2 mutation status and clinical pathologic features of 108 male breast cancer cases from Tuscany: a population based study in central Italy. Breast Cancer Res Treat, 116, 577-86.
36. Ottini L, Palli P, Rizzo I, et al (2010). Male breast cancer. Crit Rev Oncol Hematol, 73, 141-55.
37. Pant K, Dutta U (2008). Understanding and management of male breast cancer: a critical review. Med Oncol, 25, 294-98.
38. Ribeiro G, Swindell R, Harris M, Banerjee S, Cramer A (1996). A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast, 5, 141-6.
39. Romond E, Perez E, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med, 353, 1673-84.
40. Rossman E, Libjegren A, Bergh J (2007). Male breast cancer-how to treat, Breast Cancer on line, 10, 1-6.
41. Smith I, Dowsett M, Ebbs S, et al (2005). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate Preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol, 23, 5108-16.
42. Smith I, Procter M, Gelber R, et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36.
43. Swerdlow A, Schoemaker M, Higgins C, et al (2005). Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst, 97, 1204-10.
44. Taber Johansen K, Moricy L, Osbahs A, Dickinson B (2010). Male breast cancer: risk factors, diagnosis and management. Oncology Reports, 24, 1115-20.
45. Thellenberg C, Malmer B, Tavelin B, Gronberg H (2003). Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol, 169, 1345-48.
46. Trunet P, Mueller B, Bhatnagar A, et al (1993). Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab, 77, 319-23.
47. Turner K, Morley M, Atanassova N, Swanston I, Sharpe R (2000). Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol, 164, 225-38.
48. Vetto J, Jun S, Paduch D, Eppich A, Shih R (1999). Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg, 177, 379-83.
49. Willsher P, Leach I, Ellis I, et al (1997). A comparison outcome of male breast cancer with female breast cancer. Am J Surg, 173, 185-8.
50. Zabolotny B, Zalai C, Meterissian S (2005). Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol, 90, 26-30.